Fecal Immunochemical Test
FIT screenings linked to 33% lower mortality risk from colorectal cancer
Completing at least one fecal immunochemical test screening correlated with a 33% overall lower risk for death from colorectal adenocarcinoma, with a 42% reduction reported for cancers in the left colon and rectum, according to researchers.
CRC screening based on fecal hemoglobin levels could reduce other testing by up to 49%
Using fecal hemoglobin concentrations to guide colorectal cancer screening intervals reduced the number of fecal immunochemical tests and colonoscopies by 49% and 28%, respectively, compared with biennial screening, data showed.
Are new colorectal cancer screening options a match for 'the gold standard'?
New testing options for colorectal cancer will likely expand access to screening, but they are not as reliable as a colonoscopy, according to experts.
Nearly 60 million individuals aged 45 to 85 years are eligible for CRC screening in the US
Researchers estimated that nearly 60 million individuals aged 45 to 85 years are at average-risk for colorectal cancer and eligible for screening in the U.S., according to cross-sectional study data in JAMA Network Open.
Blood-based CRC screening ‘less effective, more costly’ vs. recommended strategies
Triennial blood-based screening for colorectal cancer was not cost-effective compared with existing screening modalities such as colonoscopy, fecal immunochemical test and stool DNA testing, according to microsimulation model projections.
Colorectal Cancer Awareness Month: Insights into early-onset disease, impact of diabetes
March is Colorectal Cancer Awareness Month.
Routine screening with fecal occult blood testing reduces CRC mortality by 14%
Participation in early, routine screening for colorectal cancer using fecal occult blood testing was associated with a 14% reduction in CRC mortality in a cohort of nearly 380,000 individuals in Sweden, according to data.
VIDEO: One in 10 FIT ‘unsatisfactory’ in screening for CRC, mainly due to patient error
In this Healio video, Rasmi Nair, MBBS, MPH, PhD, reports findings from a recent study, which showed 10% of at-home fecal immunological tests for colorectal cancer screening could not be processed, mostly due to specimen errors.
GI cancer screening topped headlines in 2023: Did your patients get the message?
From updates in colorectal cancer screening to developments in screening methods, Healio has been at the forefront of coverage for gastrointestinal cancer in 2023 – but has the important news made its way to your patients?
Patients with negative FIT results in upper range still at risk for advanced neoplasia
Among patients with negative fecal immunochemical tests, those with values in the upper range demonstrated higher risk for advanced neoplasia vs. those in the lower range, according to data in Annals of Internal Medicine.